Clinical trialNCT04931459CompletedPhase 1Interventional

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD

SponsorAcumen PharmaceuticalsEnrollment65Alzheimer Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when administered to participants diagnosed with Mild Cognitive Impairment (MCI) or Mild Dementia due to Alzheimer's disease (AD).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eric Siemers, MD
Acumen Pharmaceuticals, Inc.
Principal Investigator
clinicaltrials.gov ↗
Russell Barton
Acumen Pharmaceuticals, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Clinical Endpoints
Scottsdale, Arizona, United States
Orange County Research Institute
Anaheim, California, United States
Hoag Hospital Newport Beach
Newport Beach, California, United States
Velocity Clinical Research
Hallandale, Florida, United States
Charter Research
Lady Lake, Florida, United States
Columbus Clinical Services
Miami, Florida, United States
Combined Research Orlando Phase I-Iv
Orlando, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
Santos Research Center
Tampa, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Iresearch Atlanta
Decatur, Georgia, United States
Advanced Memory Research Institute of Nj
Toms River, New Jersey, United States
Columbia University
New York, New York, United States
Amc Research
Matthews, North Carolina, United States
Abington Neurological Associates
Abington, Pennsylvania, United States
Kerwin Medical Center
Dallas, Texas, United States
Clinical Trials Network
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ACU193Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Jun 2021
Primary completion: 12 Jun 2023
Completion: 12 Jun 2023
Last update posted: 19 Jul 2023
Registered enrollment: 65
Registry id: NCT04931459

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.